Physician profile
Aida Loudyi
NPI 1225152572
$9,751.44
in general payments reported to CMS, 2019-2025
29 companies · $2,859 in 2025
The $2,859 reported for 2025 was more than what 76% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $32.07 · 2021: $605 · 2022: $1,574 · 2023: $1,750 · 2024: $2,570 · 2025: $2,859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,168 · Education: $10.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,168.18 |
| Education | $10.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,315.56 | 2019-2025 | |
| Amgen INC. | $1,190.95 | 2020-2025 | Uplizna, Enbrel, Otezla |
| Ucb, INC. | $884.00 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $643.91 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $599.48 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $504.33 | 2021-2025 | Saphnelo |
| Janssen Biotech, INC. | $487.10 | 2021-2025 | Tremfya, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $482.91 | 2021-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $409.70 | 2023-2025 | Strensiq |
| Glaxosmithkline, LLC. | $368.94 | 2022-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $367.16 | 2022-2024 | Taltz, Zepbound |
| Regeneron Healthcare Solutions, INC. | $341.67 | 2022-2024 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $330.64 | 2021-2025 | Sotyktu, Orencia |
| Pfizer INC. | $204.37 | 2019-2025 | |
| Horizon Therapeutics Plc | $189.69 | 2020-2023 | Krystexxa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $186.52 | 2023-2025 | Crysvita |
| Aurinia Pharma U.S., INC. | $166.01 | 2022-2025 | Lupkynis |
| Galderma Laboratories, L.P. | $142.32 | 2024 | |
| Abbott Laboratories | $140.00 | 2024 | Freestyle Libre 3 |
| Ani Pharmaceuticals, INC. | $132.55 | 2024 | Purified Cortrophin Gel |
| Novo Nordisk INC | $124.57 | 2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $122.28 | 2022 | |
| Gilead Sciences, INC. | $121.96 | 2023 | Veklury |
| Incyte Corporation | $111.52 | 2025 | Opzelura |
| Radius Health, INC. | $68.55 | 2022-2024 | Tymlos |
| Sandoz INC. | $43.12 | 2024 | Hyrimoz |
| Kiniksa Pharmaceuticals International, Plc | $35.82 | 2024 | Arcalyst |
| Scilex Pharmaceuticals INC. | $21.79 | 2024 | |
| Genentech USA, INC. | $14.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aida Loudyi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.